IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

Blood

Volumn 125, Issue 2, 2015, Pages 296-303

  Kernytsky, Andrew ^a   Wang, Fang ^a   Hansen, Erica ^a   Schalm, Stefanie ^a,b   Straley, Kimberly ^a   Gliser, Camelia ^a   Yang, Hua ^a   Travins, Jeremy ^a   Murray, Stuart ^a   Dorsch, Marion ^a   Agresta, Sam ^a   Schenkein, David P ^a   Biller, Scott A ^a   Su, Shinsan M ^a   Liu, Wei ^a   Yen, Katharine E ^a  

^a AGIOS PHARMACEUTICALS   (United States)

^b Blueprint Medicines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; AGI 5198; GENOMIC DNA; MESSENGER RNA; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; AGI-6780; CARBANILAMIDE DERIVATIVE; ENZYME INHIBITOR; HISTONE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; SULFONAMIDE; TRANSCRIPTOME;

ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; ERYTHROLEUKEMIA; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; HISTONE METHYLATION; HUMAN; HUMAN CELL; IDH2 GENE; INDUCED MUTATION; LEUKEMIA; LYMPHOMA; MUTATOR GENE; PRIORITY JOURNAL; TUMOR GENE; ACUTE MYELOBLASTIC LEUKEMIA; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; GENETICS; LIQUID CHROMATOGRAPHY; MUTATION; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CHROMATOGRAPHY, LIQUID; DNA METHYLATION; ENZYME INHIBITORS; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MUTATION; PHENYLUREA COMPOUNDS; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; TANDEM MASS SPECTROMETRY; TRANSCRIPTOME;

EID: 84920971376     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-533604     Document Type: Article

References (34)

1. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
2. Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010;29(49):6409-6417.
3. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010;465(7300):966.
4. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483.
5. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
6. Yamane K, Toumazou C, Tsukada Y, et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell. 2006;125(3):483-495.
7. Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439(7078):811-816.
8. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626-630.
9. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622-626.
10. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625.
11. Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463-469.
12. Sean Davis PD, Sven Bilke, Tim Triche, Jr. and Moiz Bootwalla methylumi: Handle Illumina methylation data; 2012.
13. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30(10):1363-1369.
14. Aryee KDHaM. minfi: Analyze Illumina's 450k methylation arrays; 2011.
15. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100(16):9440-9445.
16. Du P, Zhang X, Huang CC, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics. 2010;11:587.
17. Cox TF, Cox MAA. Multidimensional Scaling. 2nd edition. Boca Raton, FL: CRC Press; 2001.
18. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Soc. 1995;57(1):289-300.
20. Fujita PA, Rhead B, Zweig AS, et al. The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 2011;39(Database issue):D876-D882.
21. Pronier E, Almire C, Mokrani H, et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011;118(9):2551-2555.
22. Fathi ATSH, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012;120(23):4649-4652.
23. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
24. Zilberman D. The human promoter methylome. Nat Genet. 2007;39(4):442-443.
25. Zilberman D, Gehring M, Tran RK, Ballinger T, Henikoff S. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat Genet. 2007;39(1):61-69.
26. Movassagh M, Choy MK, Goddard M, Bennett MR, Down TA, Foo RS. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS ONE. 2010;5(1):e8564.
27. Bhattacharyya S, Yu Y, Suzuki M, et al. Genomewide hydroxymethylation tested using the HELPGT assay shows redistribution in cancer. Nucleic Acids Res. 2013;41(16):e157.
28. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999;59(12):2766-2769.
29. Chen Z, Zang J, Whetstine J, et al. Structural insights into histone demethylation by JMJD2 family members. Cell. 2006;125(4):691-702.
30. Whetstine JR, Nottke A, Lan F, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006;125(3):467-481.
31. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30.
32. Tonks A, Pearn L, Musson M, et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia. 2007;21(12):2495-2505.
33. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430-446.
34. Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110(19):7922-7927.